Vaccination Uptake
Conditions
Brief summary
The CareVax project aims to find frail patients at Fondazione Policlinico Universitario 'A. Gemelli' IRCCS who could benefit from vaccinations against pneumococcal, Zoster, flu, HBV and SARS-CoV-2. This will reduce hospital stays, long-term effects, and deaths related to these diseases, as outlined in the PNPV (National Plan for Vaccine Prevention) 2017-2019 and Ministry of Health circulars from September, October, December 2022, and January 2023. Eligible patients, upon consent, will be identified by applying an automated algorithm to the patient's electronic health record and vaccination history contained in the regional vaccination registry. Identified patients will be contacted either directly if they are admitted to the inpatient wards of the Fondazione Policlinico Universitario A.Gemelli IRCCS (FPG) Hospital, or by messaging or e-mail in the case of access to the FPG for follow-up or routine visits or day hospital or day surgery service. Patients contacted, depending on their frail condition, will be booked for vaccination at an hospital vaccine clinic (extremely vulnerable patients) or a Local Health Unit (ASL Roma1) vaccine clinic respectively (frail patients). The project envisages a validation phase of the algorithm, through the evaluation of its concordance with the judgement of a blinded clinician on a small group of patients Patients' engagement and a proper communication system with them will be carried through an interoperable digital system aimed at booking the new vaccination appointment, reminding it and providing patients with all the information needed.
Interventions
OTHERcreation of a clinical pathway to increase vaccination coverage in frail patients
creation of a clinical pathway to increase vaccination coverage for frail patients, integrating hospital and local health units through an automated algorithm
Sponsors
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* 18 years old or more, * Patients who have accessed one of the enrolled departments (Dermatology, Oncological gynaecology, Geriatry, Nephrology, Gastroenterology), * Medical residence in Lazio Region
Exclusion criteria
\- Patients who do not fulfill 1 or more inclusion criteria
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Patients' drop out proportion | 24 months | Number of patients who drop out or are lost to follow-up versus the total number of patients recruited. |
| Vaccinated against influenza at 12 months | 12 months | Proportion of participants vaccinated against influenza 12 months after the beginning of the study |
| Vaccinated against influenza at 6 months | 6 months | Proportion of participants vaccinated against influenza 6 months after the beginning of the study |
| Vaccinated against COVID19 at 24 months | 24 months | Proportion of participants fully vaccinated against Covid19 24 months after the beginning of the study |
| Vaccinated against COVID19 at 12 months | 12 months | Proportion of participants fully vaccinated against Covid19 12 months after the beginning of the study |
| Vaccinated against COVID19 at 6 months | 6 months | Proportion of participants fully vaccinated against Covid19 6 months after the beginning of the study |
| Algorithm clinician concordance - initial sample of patients | At the start | Concordance between the clinician's and the algorithm's judgments on patient eligibility for vaccination, measured on a sample of patients. |
| Algorithm clinician concordance | 24 months | The proportion of vaccinations confirmed by physicians compared to those proposed by the algorithm. |
| Feasibility in reaching the patients | 24 months | Number of patients successfully contacted to offer a vaccination appointment after being considered eligible compared to the number of patients flagged by the algorithm. |
| Acceptability of the vaccination offer | 24 months | Number of patients consenting to vaccination appointments compared to the number of patients contacted. |
| Logistical feasibility of the vaccination pathway | 24 months | Number of patients presenting to vaccination centers (Hospital or Local Health Authority) compared to the number who have booked a vaccination appointment. |
| Vaccinated against influenza at 24 months | 24 months | Proportion of participants vaccinated against influenza 24 months after the beginning of the study |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Vaccinated against Herpes Zoster virus at 24 months | 24 months | Proportion of participants vaccinated against Herpes Zoster virus 24 months after the beginning of the study |
| Vaccinated against Pneumococcus at 24 months | 24 months | Proportion of participants vaccinated against Pneumococcus 24 months after the beginning of the study |
| Vaccinated against Hepatitis B virus at 12 months | 12 months | Proportion of participants vaccinated against Hepatitis B virus 12 months after the beginning of the study |
| Vaccinated against Herpes Zoster virus at 12 months | 12 months | Proportion of participants vaccinated against Herpes Zoster virus 12 months after the beginning of the study |
| Vaccinated against Pneumococcus at 12 months | 12 months | Proportion of participants vaccinated against Pneumococcus 12 months after the beginning of the study |
| Vaccinated against Hepatitis B virus at 6 months | 6 months | Proportion of participants vaccinated against Hepatitis B virus 6 months after the beginning of the study |
| Vaccinated against Herpes Zoster virus at 6 months | 6 months | Proportion of participants vaccinated against Herpes Zoster virus 6 months after the beginning of the study |
| Vaccinated against Pneumococcus at 6 months | 6 months | Proportion of participants vaccinated against Pneumococcus 6 months after the beginning of the study |
| Alerts generated by the algorithm at 24 months | 24 months | Number of vaccination alerts generated by the algorithm among the study participants in the first 24 months after the beginning of the study |
| Vaccinated against Hepatitis B virus at 24 months | 24 months | Proportion of participants vaccinated against Hepatitis B virus 24 months after the beginning of the study |
Countries
Italy
Contacts
Primary ContactPatrizia Laurenti
Outcome results
None listed